Both are monoclonal antibodies that inhibit VEGF through receptor binding, leading to the suppression of new blood vessel formation and thus to a bottleneck in tumor supply (Hurwitz et al., 2005; Garcia-Carbonero et al., 2014). This evidence concerns the gene VEGFA and neoplasm.